Drug intelligence / Profile preview

NZX

Development stage: Preclinical
Lead developer: Hamlet Biopharma
Modality: Peptides

Overview

NZX and its related variant NZ2114 are antimicrobial peptide candidates being developed by HAMLET BioPharma for the treatment of pulmonary tuberculosis, including multi-drug resistant (MDR-TB) strains. These peptides are variants of plectasin, a fungal defensin, and exert bactericidal activity by targeting Lipid II and disrupting the complex, lipid-rich cell membrane of *Mycobacterium tuberculosis*. NZ2114 has demonstrated an 81% reduction in bacterial load in murine infection models and shows high stability in serum with minimal toxicity to human cells. The program was acquired from Linnane Projects AB in March 2023 and is currently in preclinical development. HAMLET BioPharma has also partnered with ImmunoForge to develop advanced administration technology for the NZX peptide.

Other names: Anti-TBC peptideAnti-Tuberculosis Peptide

Targets

Lipid II

Beyond the preview

Go deeper on NZX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NZX.

Explore the full profile